

Press Release

29 May 2024 14:16:00 CEST

Correction: Revised Financial Calendar Announcement

Date of AGM corrected

2cureX AB has revised its financial calendar to align with its strategic shift and previously announced reductions in operational spending.

As part of this broad adjustment to business activities, and in accordance with Nasdaq guidelines, 2cureX will limit the number of quarterly reports for Q2 and Q4.

Additionally, due to reduced activities and available resources, and to ensure thorough preparation, the Annual General Meeting (AGM) has been rescheduled from June 20th to July 1st, 2024.

The updated financial calendar reflects these changes.

For more information about 2cureX:

Kenneth Graabek Johansen, Acting Chief Executive Officer & Chief Financial Officer

E-mail: kgj@2curex.com

Telephone: +45 23 49 02 27

www.2curex.com

Ole Thastrup, Vice-Chairman

E-mail: ot@2curex.com

Telephone: +45 2211 5399

www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB

Attachments

[Revised Financial Calendar Announcement](#)